KLOW

Overview

KLOW is a four-peptide blend developed in research-supply settings that combines three regenerative peptides — GHK-Cu (50 mg), BPC-157 (10 mg), and TB-500 (10 mg), collectively known as the "GLOW" stack — with the α-MSH(11–13) tripeptide KPV (10 mg). Researchers select the four-peptide format to investigate whether complementary mechanisms — copper-dependent extracellular-matrix synthesis, angiogenic and cytoprotective signaling, actin/cytoskeletal remodeling, and direct NF-κB suppression — produce additive or synergistic outcomes in models of tissue injury and inflammation that no single component covers alone.

The pharmacological logic of the stack distributes work across four compartments. GHK-Cu functions as a copper-delivery vehicle and broad gene modulator — Pickart's group has reported >50% expression changes in roughly 31% of the human genome, with ECM synthesis (collagen I/III, elastin, decorin, glycosaminoglycans) and antioxidant pathways (Nrf2/HO-1, ferritin iron blockade) prominently activated.[1][2] BPC-157 contributes a separate axis: VEGFR2-dependent angiogenesis, FAK-paxillin and Src-Caveolin-1/eNOS modulation, and broad cytoprotective coverage across gut, tendon, ligament, and CNS preclinical models.[3][6] TB-500 (Ac-LKKTETQ) is the actin-binding fragment of Thymosin β4 and is investigated for cytoskeletal G-actin sequestration, cell migration, and re-epithelialization.[7][8]

KPV is the layer that distinguishes KLOW from GLOW. Unlike its parent α-MSH, KPV does not bind melanocortin receptors; it enters cells via the PepT1 (SLC15A1) oligopeptide transporter, binds Importin-α3, and blocks nuclear translocation of NF-κB p65 while stabilizing IκBα — producing a direct intracellular suppression of inflammatory transcription at concentrations as low as 10 nM.[4][9] Layered onto the regenerative trio, KPV is positioned in research designs as the dedicated cytokine-quenching component, complementing GHK-Cu's NF-κB/p38-MAPK modulation and BPC-157's NO-system buffering. The four peptides are supplied co-lyophilized in a single 80 mg vial; no large-scale randomized human trial has been conducted on the blend itself, and all available data are from in-vitro and animal studies of the individual components.

Mechanism of Action — Per Component

GHK-Cu (50 mg) — Copper Delivery & Gene Modulation

GHK-Cu (Gly-His-Lys-Cu²⁺, ~401.9 Da) is a redox-silenced copper-tripeptide complex that delivers Cu(II) intracellularly without driving Fenton-reaction toxicity, supplying copper to enzymes such as lysyl oxidase (collagen crosslinking) and Cu/Zn-SOD (antioxidant defense).[1] Connectivity Map analysis links GHK-Cu to >50% expression changes in ~31% of human genes, biasing toward ECM synthesis (collagen I/III, elastin, decorin, GAGs), Nrf2/Keap1-driven HO-1 transcription, and suppression of NF-κB p65 / p38-MAPK phosphorylation.[2][10] Collagen-synthesis dose response is biphasic, peaking at ~10⁻⁹ M.

BPC-157 (10 mg) — Angiogenic / Cytoprotective Pentadecapeptide

BPC-157 (sequence GEPPPGKPADDAGLV, 1419 Da) is a partial sequence of a gastric body-protective compound, exceptionally stable in human gastric juice (>24 h) and active across oral, parenteral and topical routes in preclinical models.[3] Reported mechanisms include VEGFR2 internalization and Src-Caveolin-1-eNOS coupling driving NO release and angiogenesis; FAK-paxillin activation supporting fibroblast migration; homeostatic buffering of the L-NAME / L-arginine NO axis; and modulation of dopaminergic and serotonergic systems without direct receptor binding.[6][11] Tissue coverage in animal models spans tendon-to-bone reattachment, GI mucosal repair, and CNS injury.

TB-500 (10 mg) — Thymosin β4 Actin-Binding Fragment

TB-500 (Ac-LKKTETQ, ~889 Da) is a synthetic acetylated heptapeptide corresponding to the actin-binding region (residues 17–23) of full-length Thymosin β4. It interacts with G-actin sequestration and cytoskeletal dynamics that underlie cell migration, re-epithelialization and angiogenesis, with hair-follicle and corneal/dermal wound-healing read-outs in preclinical literature.[7][8] Recent metabolite work (Rahaman et al., 2024) suggests the in-vitro wound-healing signal may be carried by the metabolite Ac-LKKTE rather than the parent peptide, an important caveat when interpreting blend-level data.[12]

KPV (10 mg) — α-MSH(11–13) NF-κB Suppressor

KPV (Lys-Pro-Val, 342.4 Da) is the C-terminal tripeptide of α-MSH and operates through a melanocortin-receptor-independent pathway. It is taken up by the proton-coupled PepT1 (SLC15A1) oligopeptide transporter (Kₘ ~160 µM in Caco2-BBE intestinal epithelia), then binds Importin-α3 at armadillo domains 7–8, physically blocking nuclear import of NF-κB p65/RelA while stabilizing IκBα.[4][9] KPV additionally inhibits ERK1/2, JNK and p38 MAP kinases and has shown activity at concentrations as low as 10 nM, with antimicrobial activity against S. aureus and C. albicans across picomolar–micromolar ranges.[13]

Research Applications

KLOW combines four peptides whose individual literatures span tissue repair, angiogenesis, gene modulation, and direct anti-inflammatory signaling. Investigators using the blend explore:

1. Inflammatory Bowel Disease Models — KPV has been evaluated in murine DSS-colitis and TNBS-colitis models for PepT1-mediated reduction in NF-κB transcription; combined with BPC-157's mucosal cytoprotection, the blend is investigated for additive intestinal-barrier preservation.[13][14]
2. Wound Healing & Skin Research — GHK-Cu (collagen/elastin synthesis), BPC-157 (granulation tissue), TB-500 (keratinocyte migration), KPV (anti-inflammatory) — each independently accelerate wound closure in preclinical models. The 4-peptide combination is investigated for whether the layered mechanisms produce additive closure rates beyond any single component.
3. Recovery / Connective Tissue Models — BPC-157 and TB-500 each accelerate Achilles transection healing; GHK-Cu modulates MMP/TIMP balance; KPV reduces TNF-α and IL-1β. Combined administration is studied for connective-tissue repair models with concurrent inflammation.
4. NF-κB / Cytokine Pathway Studies — All four peptides converge on NF-κB modulation through different mechanisms: KPV via Importin-α3 blockade, GHK-Cu via p65 phosphorylation suppression, BPC-157 via NO-axis modulation, TB-500 via RelA/p65 nuclear translocation interruption.[9]
5. Antioxidant Defense Research — GHK-Cu and TB-500 upregulate Cu/Zn-SOD, Mn-SOD, and catalase. The blend is investigated for layered antioxidant capacity in oxidative-stress models.

Important: cited studies used individual peptides, not the KLOW four-peptide combination. No published peer-reviewed studies have evaluated the 50/10/10/10 blend itself.

Preclinical Research Summary (Component-Level)

No peer-reviewed studies have evaluated the KLOW 50/10/10/10 blend as a co-administered formulation. Component-level research is summarized below; for full data see the dedicated GHK-Cu, BPC-157, TB-500, and KPV entries.